Cargando…
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
BACKGROUND: Patients with metastatic breast cancer are frequently treated with anthracyclines and taxanes, which are among the most active agents in this disease. Gemcitabine is an interesting candidate for a three-drug combination because of its different mechanism of action and non-overlapping tox...
Autores principales: | Passardi, Alessandro, Massa, Ilaria, Zoli, Wainer, Gianni, Lorenzo, Milandri, Carlo, Zumaglini, Federica, Nanni, Oriana, Maltoni, Roberta, Frassineti, Giovanni Luca, Amadori, Dino |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434761/ https://www.ncbi.nlm.nih.gov/pubmed/16551351 http://dx.doi.org/10.1186/1471-2407-6-76 |
Ejemplares similares
-
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008) -
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
por: Zoli, Wainer, et al.
Publicado: (2005) -
Effectiveness of bevacizumab in first- and second-line treatment for
metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020) -
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
por: Rocca, Andrea, et al.
Publicado: (2017) -
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)